3.1.0 Bicyclic g1yt1 inhibitors and methods for their preparation and use

A C3-C12, C2-C12 technology, applied in the field of 3.1.0 bicyclic G1yT1 inhibitors and its preparation and use, can solve the problem of lack of effective inhibition of glycine transporter GlyT1

Inactive Publication Date: 2011-12-07
VANDERBILT UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although some progress has been made in the research of GlyT1 uptake inhibitors, there is still a lack of effective inhibition of the glycine transporter GlyT1 and effective treatment of neurological and psychiatric disorders associated with dysfunctional glutamatergic neurotransmission and diseases involving the glycine transporter GlyT1. compound

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 3.1.0 Bicyclic g1yt1 inhibitors and methods for their preparation and use
  • 3.1.0 Bicyclic g1yt1 inhibitors and methods for their preparation and use
  • 3.1.0 Bicyclic g1yt1 inhibitors and methods for their preparation and use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0052] The present invention may be understood more readily by reference to the following description and examples included therein.

[0053] Before the compounds, compositions, articles, systems, devices and / or methods of the present invention are disclosed and described, it is to be understood that, unless otherwise specified, they are not limited to particular synthetic methods, or unless otherwise specified, are not limited to particular reagents, so this may of course vary. It is also to be understood that terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are now described.

[0054] All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and / or materials in connection with whic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to compounds useful as inhibitors of type 1 glycine transporter (GlyT1) activity; synthetic methods for preparing said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds and compositions for the treatment of patients with type 1 A method for disorders related to glycine transporter (GlyT1) activity.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Application Serial No. 61 / 141,030, filed December 29, 2008, which is hereby incorporated by reference in its entirety. Background technique [0003] Schizophrenia is a disorder characterized by a combination of negative symptoms (blunted affect, withdrawal, anhedonia) and positive symptoms (paranoids, hallucinations, delusions) and marked cognitive impairment Debilitating mental illness. Although the etiology of schizophrenia is currently unknown, the disorder appears to result from a complex interplay of biological, environmental, and genetic factors. More than forty years ago, it was discovered that phencyclidine (PCP) can induce a psychotic state in humans, which is very similar to that observed in patients with schizophrenia. The main mode of action of PCP is the noncompetitive antagonist mode of action of the ionotropic glutamate receptor N-methyl-D-aspartate (NMDA) subty...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/397A61K31/407
CPCC07D403/12C07D401/12C07D401/14C07D401/04C07D209/52A61P13/10A61P21/00A61P25/00A61P25/04A61P25/08A61P25/14A61P25/16A61P25/18A61P25/20A61P25/22A61P25/24A61P25/28A61P25/30A61P25/32A61P25/34A61P25/36A61P27/02A61P27/16A61P29/00A61P3/04A61P43/00A61K31/407A61K31/397A61K31/4164
Inventor 克雷格·W·林斯利P·杰弗里·康恩查尔斯·戴维·韦弗科琳·M·尼斯温德理查德·威廉斯卡丽·K·琼斯道格拉斯·J·谢弗勒
Owner VANDERBILT UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products